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Introduction
Osteoporosis is a systemic skeletal condition that caus-
es reduction of the bone mass. The incidence of osteo-
porosis increases with age, and its greatest risk is bone 
fracture, which results in a decreased quality of life.1,2 
Bisphosphonates are widely used treatment agents for os-
teoporosis due to their suppression of osteoclast activity, 
which slows down the bone remodeling process and in-
creases the bone mineral density.1,3-10
Bisphosphonates are known to suppress bone resorption 
that occurs during the normal healing process, thereby 
delaying bone healing. Bisphosphonate-related osteo-
necrosis of the jaw (BRONJ) is the main side effect of 
bisphosphonate; it was first reported in 2003 by Marx11 
and can be defined as follows:12,13 1) exposed bone in the 
maxillofacial region that is present for 8 weeks or more, 2) 
current or previous bisphosphonate use, and 3) no history 
of radiation therapy to the jaws. The exact etiopathology 
of BRONJ is not well known, but several factors that af-
fect its development have been reported. Dental surgery is 
one of these factors, and tooth extraction is known to be a 
high-risk procedure because of the production of a bony 
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Purpose: The aim of this study was to investigate the incidence of bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) after tooth extraction in patients with osteoporosis on oral bisphosphonates in Korea and to evaluate local 
factors affecting the development of BRONJ.
Materials and Methods: The clinical records of 320 patients who underwent dental extraction while receiving 
oral bisphosphonates were reviewed. All patients had a healing period of more than 6 months following the 
extractions. Each patient’s clinical record was used to assess the incidence of BRONJ; if BRONJ occurred, a further 
radiographic investigation was carried out to obtain a more definitive diagnosis. Various local factors including age, 
gender, extraction site, drug type, duration of administration, and C-terminal telopeptide (CTx) level were retrieved 
from the patients’ clinical records for evaluating their effect on the incidence of BRONJ.
Results: Among the 320 osteoporotic patients who underwent tooth extraction, 11 developed BRONJ, reflecting 
an incidence rate of 3.44%. Out of the local factors that may affect the incidence of BRONJ, gender, drug type, 
and CTx level showed no statistically significant effects, while statistically significant associations were found for 
age, extraction site, and duration of administration. The incidence of BRONJ increased with age, was greater in the 
mandible than the maxilla, and was associated with a duration of administration of more than 3 years.
Conclusion: Tooth extraction in patients on oral bisphosphonates requires careful consideration of their age, the 
extraction site, and the duration of administration, and close postoperative follow-up should be carried out to 
facilitate effective early management. (Imaging Sci Dent 2017; 47: 45-50)
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socket.
In the Korean population that takes bisphosphonates for 
osteoporosis, the incidence of BRONJ after tooth extrac-
tion has been rarely reported. Therefore, whether tooth 
extraction is a causative factor of BRONJ in patients with 
osteoporosis is uncertain. In this study, we aimed to in-
vestigate the incidence of BRONJ after tooth extraction 
in patients with osteoporosis exposed to oral bisphospho-
nates and to evaluate the local factors that affect the de-
velopment of BRONJ.
Materials and Methods
In all, 320 patients were selected as the subjects for this 
study; these patients were on oral bisphosphonates treat-
ment for osteoporosis and underwent tooth extraction at 
Yonsei University Dental Hospital. This study was ap-
proved by the Institutional Review Board (IRB) of Yonsei 
University Dental Hospital (Approval number: 13-0114 
(2-2013-0062)). Written or verbal informed consent was 
not obtained from any participants because the IRB waived 
the need for individual informed consent, as this study 
had a non-interventional retrospective design and all data 
were analyzed anonymously. The reasons for tooth extrac-
tion included periodontitis, residual root, advanced dental 
caries, and tooth fracture. In all, 651 teeth were selected, 
which included 94 maxillary anterior teeth, 84 maxillary 
premolars, 187 maxillary molars, 74 mandibular anterior 
teeth, 67 mandibular premolars and 145 mandibular mo-
lars.
Tooth extractions were performed using routine proto-
cols as follows: All patients received prophylactic anti-
biotics 1 hour prior to the extractions, which were carried 
out under local anesthesia. The extraction sockets were 
sutured. Antibiotic, anti-inflammatory, and analgesic drugs 
were prescribed for 3 days. The minimum follow-up pe-
riod following the extraction was 6 months. A definitive 
diagnosis of BRONJ was made using the patients’ clinical 
records, including the presence of clinical symptoms and 
radiographic findings. At the time of extraction, various 
local factors, data regarding which were gathered from 
the clinical records, were recorded as follows: 1) gender: 
male or female; 2) age: below 65 years or over 65 years; 
3) extraction site: maxilla or mandible (anterior, premolar, 
or molar); 4) drug type: alendronate, ibandronate, or rise-
dronate; 5) duration of administration: less than 3 years 
or more than 3 years; and 6) C-terminal telopeptide (CTx) 
level (pg/mL): below 150 or over 150.
A statistical analysis was carried out to determine the 
difference in the rate of incidence according to each fac-
tor by using the chi-square test in SPSS version 20.0 (IBM 
Corp., Armonk, NY, USA).
Results
Incidence according to gender and age
In all, 11 of the 320 patients with osteoporosis devel-
oped BRONJ, with an incidence rate of 3.44%. The inci-
dence of BRONJ according to gender and age is as pre-
sented in Table 1. The number of male patients with oste-
oporosis was only 22, which was considerably less than 
that of female patients; therefore, comparisons according 
to gender may not be absolutely reliable. However, no 
statistically significant difference was observed accord-
ing to gender with respect to the incidence rate. No male 
patients with osteoporosis developed BRONJ, and all pa-
tients who developed BRONJ were female. A statistically 
significant difference was found in the rate of incidence 
with respect to the age group, as all 11 patients who de-
veloped BRONJ were over 65 years old.
Incidence according to extraction site
The incidence of BRONJ according to the extraction 
site is presented in Table 2. In all, 651 teeth were extract-
ed. Three of the 365 maxillary teeth (0.82%) and 15 of the 
286 mandibular teeth (5.24%) developed BRONJ. There-
fore, mandibular teeth showed a greater rate of incidence 
of BRONJ than the maxillary teeth; this difference was 
Table 1. Prevalence of bisphosphonate-related osteonecrosis of the jaw according to the gender and age
Gender (n=320) Age, years (n=320)
Male Female P-value <65 >65 P-value
BRONJ 0 11
.451
0 11
.008*No BRONJ 22 287 111 198Total 22 298 111 209
Incidence (%) 0 3.69 0 5.26
*Statistically significant difference at P<.05, BRONJ: bisphosphonate-related osteonecrosis of the jaw
- 47 -
Ho-Gul Jeong et al
statistically significant. Representative cases of BRONJ 
are shown in Figures 1-3.
Incidence according to drug type, duration of 
administration, and CTx level
The incidence rate of BRONJ according to the drug 
type, duration of administration, and CTx level is present-
ed in Table 3. Patients on ibandronate showed the highest 
incidence rate (5.0%); however, no statistically significant 
difference was found according to the drug type. With re-
spect to the duration of administration, the incidence rate 
was higher (7.96%) in patients who were administered 
the drugs for more than 3 years, which was significantly 
higher than was observed in those with a drug adminis-
tration period of less than 3 years. The incidence rate was 
slightly higher in patients with a CTx level of less than 
150 pg/mL, but this finding was not statistically signifi-
cant.
Discussion
The key pharmacological mechanism of bisphospho-
nates as a treatment agent for osteoporosis is known to be 
the suppression of osteoclast activity and the subsequent 
prevention of bone resorption. Consequently, the bone 
turnover rate is reduced in patients who take bisphospho-
nates, which slows down wound healing in extraction 
sockets and increases susceptibility to complications.1 In 
a previous study, the overall disease rate of BRONJ in 
patients on bisphosphonates was estimated to be around 
0.03%-0.1%,14 and the rate of incidence was reported to 
increase following surgical procedures such as tooth ex-
traction.1,15-17 Osteoporosis is a disease of the elderly, for 
whom tooth extraction is one of the most common treat-
ment modalities. However, insufficient statistical data 
have been reported on the rate of incidence of BRONJ 
after extraction in this age group. In this study, the inci-
dence rate of BRONJ following tooth extraction was in-
vestigated in patients on oral bisphosphonates, and local 
factors potentially affecting the incidence rate were eval-
uated.
In the current study, the incidence rate of BRONJ in 
patients on oral bisphosphonates who underwent tooth 
extraction was 3.44%, which is higher than that reported 
in previous studies. This was because the previous re-
search presumably involved a wider pool of patients than 
the current study, which was limited to patients who un-
derwent tooth extraction. In the study of Taylor et al.18 in 
Fig. 1. Panoramic radiographs of a bisphosphonate-related osteonecrosis of the jaw (BRONJ) patient. Three months prior to the extraction 
of the right mandibular incisor (left) and 1 year after the extraction (right).
Table 2. Prevalence of bisphosphonate-related osteonecrosis of the jaw according to the extraction sites
Maxilla (n=365) Mandible (n=286)
P-value
Ant Pre Mol Ant Pre Mol
BRONJ 0 2 1 5 2 8
<.001*No BRONJ 94 82 186 69 65 137Total 94 84 187 74 67 145
Incidence (%) 0 2.38 0.53 6.76 2.99 5.52
*Statistically significant difference at P<.05, BRONJ: bisphosphonate-related osteonecrosis of the jaw, Ant: anterior teeth, Pre: premolars, Mol: molars
Risk factors of osteonecrosis of the jaw after tooth extraction in osteoporotic patients on oral bisphosphonates
- 48 -
which methods similar to those used in the current study 
were utilized, 5 (2.5%) out of 202 patients developed 
BRONJ, showing comparable results. A retrospective 
study by Sedghizadeh et al.19 of 66 patients who were 
taking alendronate and had undergone extraction reported 
a higher incidence (6%) of BRONJ development than was 
Fig. 2. Panoramic radiographic view of a bisphosphonate-related osteonecrosis of the jaw (BRONJ) patient prior to the extraction of the 
root remnant of the right mandibular first molar (upper left) and panoramic view (upper right); computed tomographic scan (lower) taken 1 
year after the extraction.
Fig. 3. Panoramic radiographic images of a bisphosphonate-related osteonecrosis of the jaw (BRONJ) patient prior to the extraction of the 
right mandibular first and second molars (left), and 6 months after the extraction (right).
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found in our study. Hansen et al.20 reported that among 
the osteoporosis patients on oral bisphosphonate, the in-
cidence rate of BRONJ following dental treatment was 
2.27%, which is higher than the general consensus.
Although the male subjects of this study were consid-
erably fewer in number than the female subjects, there 
was no statistically significant difference with respect to 
the incidence of BRONJ. Taylor et al.18 demonstrated that 
male patients were significantly more likely to develop 
BRONJ after tooth extraction than females, but this dif-
ference in outcome might have been caused by the intra-
venous administration of bisphosphonates in 6 of the 7 
BRONJ patients suffering from malignant tumors.
The incidence rate of BRONJ showed a statistically sig-
nificant difference between groups above and below the 
age of 65 years. The groups were divided at 65 years, as 
was done in a previous study by Taylor et al.,18 in which 
there was no statistically significant difference according 
to age; however, the inclusion of patients with malignan-
cies makes a direct comparison with the current study in-
appropriate. As all 11 patients with BRONJ in this study 
were over the age of 65 years, age can be considered a 
significant factor affecting the incidence of BRONJ.
The location of the extracted tooth was shown to be a 
significant determinant of the occurrence of BRONJ, as 
BRONJ occurred more frequently in the mandible than 
the maxilla. However, no variation within the dental arch 
was detected. Similarly, in previous research, Pazianas 
et al.1 reported that in 16 out of 22 patients, BRONJ oc-
curred in the maxilla; in the rest of the cases, it occurred 
in the mandible. Further, O’Ryan and Lo14 reported that 
BRONJ occurrence in the mandible was twice as com-
mon as in the maxilla.
With respect to the drug type, ibandronate showed the 
highest incidence rate of BRONJ, although its small sam-
ple size may have caused discrepancies in the result. This 
result is in concurrence with a previous report that sug-
gested that there was no statistically significant difference 
in the incidence rate of BRONJ among different drug 
types.1 However, further research is needed for a more ac-
curate statistical analysis in a larger sample size.
In the current study, the incidence rate of BRONJ was 
compared and evaluated after 3 years of drug adminis-
tration, a period determined by a study by Saia et al.,3 in 
which an increased risk of BRONJ was reported in sub-
jects who received oral nitrogen-containing bisphospho-
nates for more than 3 years. An incidence rate of 7.96% 
was reported in patients with more than 3 years of drug 
administration, whereas an incidence of 1.43% was re-
ported in patients with less than 3 years of administration, 
which was a statistically significant difference. Pazianas 
et al.1 reported that the period of administration had no 
relationship with the incidence of BRONJ, with 3 out of 9 
BRONJ patients having less than 3 years and the other 6 
patients having more than 3 years of drug administration. 
However, direct comparisons with the results of the cur-
rent study cannot be drawn, as the subjects were selected 
from patients already affected by BRONJ. According to 
the results of the current study, the length of the drug ad-
ministration period had a greater significance in predict-
ing the probability of BRONJ occurrence than the drug 
type.
The CTx level as an indirect numerical indicator of 
osteoclast activity has been suggested to be mandatory 
for consideration prior to tooth extractions, with a cut-
off point of 150 pg/mL.21 Lazarovici et al.15 claimed that 
the CTx level cannot be a definitive predictor of BRONJ 
incidence but may play an important role in the preoper-
ative risk assessment. In this study, the incidence rate of 
BRONJ was higher in the group with a CTx level of less 
than 150 pg/mL, but not to a statistically significant ex-
tent; this result is comparable to that of previous studies.
Various local factors may affect the incidence rate of 
BRONJ; among those, age, site of extraction, and the 
Table 3. Prevalence of bisphosphonate-related osteonecrosis of the jaw according to drug type, duration of administration, and CTx level
Drug type
P-value
Duration of 
administration 
(years) P-value
CTx level  
(pg/mL) P-value
Alen Iban Rise <3 >3 <150 >150
BRONJ 8 1 0
.152
2 9
.011*
3 3
.335No BRONJ 153 19 73 138 104 65 142Total 161 20 73 140 113 68 145
Incidence (%) 4.97 5.0 0 1.43 7.96 4.41 2.07
*Statistically significant difference at P<.05, BRONJ: bisphosphonate-related osteonecrosis of the jaw, CTx: C-terminal telopeptide, Alen: alendronate, 
Iban: iIbandronate, Rise: risedronate
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drug administration period can be considered to be im-
portant factors. Therefore, among the patients on oral bi-
sphosphonates for the treatment of osteoporosis, greater 
care needs to be taken for those who are older than 65 
years and for those with a period of administration longer 
than 3 years. In addition, close follow-up is necessary in 
the case of BRONJ incidence so that appropriate treat-
ment can be delivered in the early phase of the condition.
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